By SA Transcripts : Neurocrine Biosciences , Inc. (NASDAQ: NBIX ) Morgan Stanley Healthcare Conference Call September 10, 2014 11:30 AM ET Executives Kevin Gorman - Chief Executive Officer
There were no blockbuster announcements from Neurocrine Biosciences (NASDAQ: NBIX ) this quarter, but the company now has ..... Dyskinesia The most important update from Neurocrine Biosciences concerned its plans for Phase III testing
Neurocrine Biosciences , Inc. (NASDAQ: NBIX ) Q2 2014 Earnings Conference Call August 7, 2014 08 ..... Presentation Operator Good day, everyone and welcome to Neurocrine Biosciences Second Quarter Earnings Call. At this time, all participants
Neurocrine Biosciences (NASDAQ: NBIX ): Q2 EPS of -$0.18 in-line. Press Release Post your comment!
INWK , IO , ITMN , IXYS , JACK , KEG , KND , KW , LGP , LHCG , LNT , MBI , MCP , MG , MHLD , MNTX , MRIN , MTDR , MUSA , MWE , NBIX , NLY , NPSP , NRP , NVAX , NVTL , OILT , OSUR , PAA , PACD , PKT , PMT , PPO , PRI , PRU , PRXL , PTLA , QEP , RAIL , REG
On Monday, Neurocrine Biosciences NBIX accelerated its anticipated filing date for indiplon capsules to the second quarter of 2007 instead of 2009. We're placing Neurocrine
We are no longer providing equity research on Neurocrine Biosciences NBIX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
Neurocrine Biosciences NBIX still lacks a compelling late-stage drug candidate. Its indiplon program is dead for now; the company is still waiting on final
We're placing Neurocrine Bioscience's NBIX fair value estimate under review following the receipt of its second approvable letter for indiplon. We plan a significant reduction
Neurocrine Biosciences NBIX announced the resubmission of its new drug application for indiplon capsules on July 31. This does not change our fair value estimate